VCEL at a glance
Vericel Corp (VCEL, SEC CIK 887359) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on July 30, 2026, an 8-K current report on July 30, 2026 and Form 4 insider filings as recently as August 14, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Vericel Corp (VCEL) reported revenue of $276.3 million (up 16.5% from FY2024) and net income of $16.5 million. Diluted EPS was $0.32.
- As of June 30, 2026, 33 institutional investment managers tracked by SignalX reported holding Vericel Corp (VCEL) shares worth $977.3 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by MCLAUGHLIN KEVIN F on August 12, 2026 of 7,000 shares at $44.53 per share.
- In the last 90 days, VCEL insiders reported 0 open-market purchases ($0) and 5 open-market sales ($1.0M) on Form 4, a net sale of $1.0M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $276.3M
- +16.5% vs prior year
- Insiders · 90 days
- 0 buys · 5 sells
- Net −$1.0M
- 13F holders
- 33 funds
- $977.3M · +1 vs prior quarter
- Latest 8-K
- Jul 30, 2026
- Current report
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business: advanced autologous cell therapies and specialty biologics for sports medicine and severe burn care markets
- New product launch: MACI Arthro arthroscopic delivery system approved August 2024 and commercially available Q3 2024 with custom instruments
- Strategic shift: expanded target surgeon base from 5,000 to 7,000 to include high-volume arthroscopic knee cartilage repair surgeons
- Notable metric: MACI commercial team expanded by ~30% in late 2025 to support growth initiatives
- Unique fact: Initiated MASCOT clinical trial in Q4 2025, first randomized study of MACI for ankle cartilage defects (osteochondral lesion of the talus)
Risk Factors
- Regulatory risk: potential penalties from FDA or state agencies for off-label promotion or anti-kickback/anti-bribery law violations
- Geopolitical risk: supply disruption of NexoBrid due to Middle East conflicts or China-Taiwan tensions, impacting commercial success
- Operational risk: dependency on third-party manufacturer Matricel GmbH for critical components of MACI/Epicel cell manufacturing
- Market disruption risk: competitive pressure from emerging artificial intelligence technologies affecting product innovation and adoption
- Financial risk: key-person dependency on senior manufacturing, quality, and management personnel critical to ongoing operations
Management Discussion & Analysis
- Revenue not explicitly stated, but sales volume increase indicated by accounts receivable growth and higher net income $16.5M in 2025 vs $10.4M in 2024
- Net income $16.5M (2025), operating expenses include $38.8M stock compensation, no explicit margin % reported
- Operating cash flow $51.9M (2025) vs $58.2M (2024); investing cash outflows $44M net in 2025 vs $79M in 2024; financing cash inflows $7.1M (2025) vs $19M (2024) from stock option exercises less tax withholdings
- Management expects current liquidity (cash + investments + borrowing capacity) sufficient for 12+ months; risks include R&D pace, clinical trials, patent costs, manufacturing capacity, acquisitions, and macroeconomic factors
AI summary of the VCEL 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Q2 revenue $77.5M, up 22.5% YoY from $63.2M, driven by MACI and Epicel
- Operating margin 0.6% vs (3.2)% YoY; net income $2.2M vs $0.6M loss
- Best performer MACI revenue $65.5M, up 22.5%; worst performer NexoBrid $1.5M, up 32.5%
- Cash, equivalents and restricted cash increased $25.3M in six months; operating cash flow $32.6M vs $14.8M
- $200.0M share-repurchase authorization; outlook includes U.K. MACI approval efforts and manufacturing, supply-chain and reimbursement headwinds
Risk Factors
- No material changes to 2025 Form 10-K risk factors as of July 30, 2026
- Carried-forward risk: undisclosed or currently immaterial risks could impair business or results of operations
- Carried-forward risk: identified factors could materially adversely affect results of operations or financial condition
AI summary of the VCEL 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item EX-99.1: Item EX-99.1
- Q2 revenue rose 22% to $77.5M, led by MACI growth of 23% to $65.5M
- Net income reached $2.2M versus a $0.6M loss, while free cash flow surged to $14.3M
Item 5.03: Amendments to Articles of Incorporation or Bylaws
- Bylaws amended effective May 18, 2026 to reflect Vericel’s new global headquarters
- Principal executive office relocated to 25 Blue Sky Drive, Burlington, Massachusetts 01803
AI summaries of VCEL 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for VCEL
Don't miss the next VCEL filing
- Alerts as it files. A push when VCEL files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut VCEL, by share count.
- Ask anything. An AI agent that reads every VCEL filing and answers with sources.
VCEL alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| MCLAUGHLIN KEVIN F | Sell | Aug 12, 2026 | 7,000 | $44.53 |
| MCLAUGHLIN KEVIN F | M | Aug 12, 2026 | 7,000 | - |
| MCLAUGHLIN KEVIN F | M | Aug 12, 2026 | 7,000 | $13.05 |
| Halpin Michael | M | Aug 3, 2026 | 10,000 | $16.66 |
| Halpin Michael | Sell | Aug 3, 2026 | 10,000 | $46.84 |
| Halpin Michael | M | Aug 3, 2026 | 10,000 | - |
| SIEGAL JONATHAN | M | Jul 30, 2026 | 500 | $29.82 |
| SIEGAL JONATHAN | Sell | Jul 30, 2026 | 2,500 | $48.90 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $197.5M | $237.2M | $276.3M |
| Gross Profit | - | $172.1M | $205.6M |
| Operating Income | - | $4.5M | $11.0M |
| Net Income | - | $10.4M | $16.5M |
| Gross Margin | - | 72.6% | 74.4% |
| Op. Margin | - | 1.9% | 4.0% |
| Net Margin | - | 4.4% | 6.0% |
| Balance Sheet | |||
| Total Assets | - | $432.7M | $488.0M |
| Equity | $226.0M | $292.0M | $354.6M |
| ROE | - | 3.5% | 4.7% |
| Per Share | |||
| EPS | - | $0.20 | $0.32 |
| Cash Flow | |||
| Operating CF | - | $58.2M | $51.9M |
| CapEx | - | $64.0M | $27.2M |
Source: XBRL data in Vericel Corp (VCEL)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate VCEL share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 33 | $977.3M |
| Q1 2026 | 32 | $683.5M |
| Q4 2025 | 31 | $815.6M |
| Q3 2025 | 29 | $691.1M |
| Q2 2025 | 27 | $977.7M |
| Q1 2025 | 25 | $686.0M |
| Q4 2024 | 24 | $744.2M |
| Q3 2024 | 21 | $316.6M |
- BlackRock+326.9K (+4%)
- AQR Capital Management+234.6K (+482%)
- D.E. Shaw & Co+156.7K (+53%)
- State Street Corp+141.8K (+4%)
- Two Sigma Investments+96.0K (+20%)
- Goldman Sachs Group−228.5K (-30%)
- Citadel Advisors LLC−104.7K (-92%)
- Bank of America Corp−82.6K (-8%)
- Fifth Third Bancorp−71.6K (-28%)
- Morgan Stanley−66.4K (-14%)
- Allstate+16.6K
- Blackstone Group+7.7K
- Citizens Financial Group+5.5K
Source: 13F-HR filings on SEC EDGAR (aggregated from 222 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
VCEL filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Aug 14, 2026 | - | - | - |
| 4 | Aug 5, 2026 | - | - | - |
| 4 | Jul 31, 2026 | - | - | - |
| 8-K | Jul 30, 2026 | - | Analysis | - |
| 10-Q | Jul 30, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Jun 30, 2026 | - | - | - |
| 4 | Jun 30, 2026 | - | - | - |
| 4 | Jun 30, 2026 | - | - | - |
| 4 | Jun 30, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 4, 2026 | - | - | |
| 8-K | May 18, 2026 | - | Analysis | |
| 4 | May 15, 2026 | - | - | |
| 4 | May 13, 2026 | - | - | |
| 4 | May 8, 2026 | - | - | |
| 4 | May 8, 2026 | - | - | |
| 8-K | May 7, 2026 | - | - | |
| 10-Q | May 7, 2026 | Mar 31, 2026 | Analysis | |
| 4 | May 1, 2026 | - | - | - |
| 4 | May 1, 2026 | - | - | - |
| 4 | May 1, 2026 | - | - | - |
| 4 | May 1, 2026 | - | - | - |
| 8-K | May 1, 2026 | - | Analysis | - |
| 4 | May 1, 2026 | - | - | - |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
VCEL SEC filings: frequently asked questions
Are VCEL insiders buying or selling?
In the last 90 days, Vericel Corp (VCEL) officers, directors and 10% owners reported no open-market purchases and 5 open-market sales worth $1.0 million by 3 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold VCEL stock?
As of June 30, 2026, the largest Vericel Corp (VCEL) holders among the 13F filers tracked by SignalX were BlackRock ($360.0 million), State Street Corp ($146.6 million), Vanguard Capital Management LLC ($100.4 million), Vanguard Portfolio Management LLC ($47.2 million), Bank of America Corp ($45.2 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was VCEL's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Vericel Corp (VCEL) reported revenue of $276.3 million (up 16.5% from FY2024) and net income of $16.5 million. Diluted EPS was $0.32. The figures come from the XBRL data in the 10-K.
What are the main risks in VCEL's latest 10-K?
In the 10-K filed February 26, 2026, Vericel Corp (VCEL) flagged: Regulatory risk: potential penalties from FDA or state agencies for off-label promotion or anti-kickback/anti-bribery law violations. Geopolitical risk: supply disruption of NexoBrid due to Middle East conflicts or China-Taiwan tensions, impacting commercial success. (AI summary of the Risk Factors section.)
What did VCEL report in its latest 8-K?
Vericel Corp (VCEL) filed an 8-K on July 30, 2026. Q2 revenue rose 22% to $77.5M, led by MACI growth of 23% to $65.5M.
What are the latest VCEL SEC filings?
Vericel Corp (VCEL) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on July 30, 2026, an 8-K current report on July 30, 2026 and a Form 4 insider filing on August 14, 2026.
What is VCEL's SEC CIK number?
Vericel Corp (VCEL)'s SEC Central Index Key (CIK) is 887359. EDGAR lists every VCEL filing under that number.
Ask anything about VCEL
The research agent reads VCEL's filings, financials, insider trades and 13F holders, then answers with sources.